ZNO
0.065
66.7%
DUB
0.021
-44.7%
RLL
0.003
50%
CHM
0.005
-37.5%
DTR
0.052
40.5%
OFX
0.86
-34.6%
MM1
0.22
40.1%
DTZ
0.062
-28.7%
ALY
0.007
40%
CDEDC
0.005
-28.6%
ANR
0.007
40%
RDN
0.005
-28.6%
LTP
0.39
39.3%
EPX
0.021
-25%
CTO
0.004
33.3%
GTR
0.003
-25%
OVT
0.004
33.3%
DAL
0.023
-23.3%
ADO
0.009
28.6%
AUG
0.027
-20.6%
ATV
0.009
28.6%
ICG
0.004
-20%
LM1
0.165
26.9%
PHO
0.065
-18.8%
AVE
0.005
25%
PEK
0.275
-17.9%
KSN
0.115
25%
GBE
0.024
-17.2%
PPY
0.015
25%
FBR
0.005
-16.7%
RGL
0.005
25%
ARV
0.006
-14.3%
8CO
0.021
23.5%
AZL
0.006
-14.3%
JCS
0.033
22.2%
BLU
0.006
-14.3%
MRR
0.011
22.2%
ENL
0.03
-14.3%
MPK
0.6
21.2%
GLL
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Chimeric Therapeutics (ASX:CHM): Reports first patient enrolled in chm clinical trial

Chimeric Therapeutics (ASX:CHM) has reported that the first participant has been enrolled in the Phase 1/2 multi-center clinical trial for CHM CDH17 cell therapy.

🩺 This therapy targets advanced gastrointestinal cancers like colorectal cancer, gastric cancer, and neuroendocrine tumors.
🏆 The trial aims to find the recommended dose and assess safety and effectiveness.

ASX announcement: https://announcements.asx.com.au/asxpdf/20240722/pdf/065szt55mn24fq.pdf

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved